Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells

Journal of Translational Medicine

Volumn 5, Issue , 2007, Pages

  Deola, Sara ^a,d   Scaramuzza, Samantha ^a   Birolo, Roberto Sciarretta ^a   Cergnul, Massimiliano ^b   Ficara, Francesca ^a   Dando, Jonathan ^a   Voena, Claudia ^b,e   Vai, Sergio ^b   Monari, Marta ^b   Pogliani, Enrico ^c   Corneo, Gianmarco ^c   Peccatori, Jacopo ^b   Selleri, Silvia ^d,f   Bordignon, Claudio ^b   Roncarolo, Maria Grazia ^a   Aiuti, Alessandro ^a   Bregni, Marco ^b  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; IMMUNOGLOBULIN; NERVE GROWTH FACTOR RECEPTOR; RETROVIRUS VECTOR; SYNDECAN 1;

APHERESIS; ARTICLE; BONE MARROW PURGING; CANCER RESISTANCE; CD34 SELECTION; CELL BASED GENE THERAPY; CELL MOTILITY; CELL POPULATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; EX VIVO STUDY; GENE REARRANGEMENT; GENETIC CODE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MULTIPOTENT STEM CELL; MYELOMA CELL; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PLASMA CELL; TARGET CELL; VIRAL GENE DELIVERY SYSTEM; CELL DIVISION; CULTURE TECHNIQUE; GENETIC TRANSDUCTION; GENETICS; METABOLISM; METHODOLOGY; PATHOLOGY; RETROVIRUS; STEM CELL MOBILIZATION; TUMOR VOLUME;

ANTIGENS, CD34; BLOOD COMPONENT REMOVAL; CELL CULTURE TECHNIQUES; CELL DIVISION; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MULTIPLE MYELOMA; PLASMA CELLS; RETROVIRIDAE; TRANSDUCTION, GENETIC; TUMOR BURDEN;

EID: 34548043039     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-5-35     Document Type: Article

References (33)

1. Fermand JP Ravaud P Chevret S Divine M Leblond V Belanger C Macro M Pertuiset E Dreyfus F Mariette X Boccacio C Brouet JC High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: Up-front or Rescue Treatment? Results of a Multicenter Sequential Randomized Clinical Trial Blood 1998 92 3131-3136 9787148
2. Child JA Morgan GJ Davies FE Owen RG Bell SE Hawkins K Brown J Drayson MT Selby PJ Medical Research Council Adult Leukaemia Working Party High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 2003 348 1875-83 10.1056/NEJMoa022340 12736280
3. Attal M Harousseau JL Facon T Guilhot F Doyen C Fuzibet JG Monconduit M Hulin C Caillot D Bouabdallah R Voillat L Sotto JJ Grosbois B Bataille R InterGroupe Francophone du Myelome Single versus double autologous stem-cell transplantation for multiple myeloma N Engl J Med 2003 349 2495-502 10.1056/NEJMoa032290 14695409
4. Schiller G Vescio R Freytes C Spitzer G Sahebi F Lee M Wu CH Cao J Lee JC Hong CH Lichtenstein A Lill M Hall J Berenson R Berenson J Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemoterapy for patients with advanced multiple myeloma Blood 1995 86 390-397 7540888
5. Lemoli RM Fortuna A Motta MR Rizzi S Giudice V Nannetti A Martinelli G Cavo M Amabile M Mangianti S Fogli M Conte R Tura S Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myelma patients: Positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells Blood 1996 87 1625-1634 8608257
6. Vogel W Kopp HG Kanz L Einsele H Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation J Cancer Res Clin Oncol 2005 131 4 214-8 10.1007/ s00432-004-0635-y 15616828
7. Gertz MA Witzig TE Pineda AA Greipp PR Kyle RA Litzow MR Monoclonal plasma cell in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse free survival after transplantation Bone marrow Transplant 1997 19 337-342 10.1038/ sj.bmt.1700670 9051243
8. Stewart AK Vescio R Schiller G Ballester O Noga S Rugo H Freytes C Stadtmauer E Tarantolo S Sahebi F Stiff P Meharchard J Schlossman R Brown R Tully H Benyunes M Jacobs C Berenson R White M DiPersio J Anderson KC Berenson J Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial J Clin Oncol 2001 19 3771-3779 11533101
9. Lemoli RM Martinelli G Zamagni E Motta MR Rizzi S Terragna C Rondelli R Ronconi S Curti A Bonifazi F Tura S Cavo M Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemoterapy Blood 2000 95 2234-2239 10733490
10. Gazitt Y Reading CC Hoffman R Wickrema A Vesole DH Jagannath S Condino J Lee B Barlogie B Tricot G Purified CD34+Lin-Thy+ stem cells do not contain clonal myeloma cells Blood 1995 86 381-389 7540887
11. Michallet M Philip T Philip I Godinot H Sebban C Salles G Thiebaut A Biron P Lopez F Mazars P Roubi N Leemhuis T Hanania E Reading C Fine G Atkinson K Juttner C Coiffier B Fiere D Archimbaud E Transplantation with selected autologous peripheral blood CD34+Thy+ hematopoietic stem cells (HSCs) in multiple myeloma: Impact of HSC dose on engraftment, safety, and immune reconstitution Exp Hematol 2000 28 858-870 10.1016/ S0301-472X(00)00169-7 10907648
12. Altes A Sierra J Esteve J Martin-Henao G Marin P Sureda A Briones J Martino R Villamor N Colomer D Carreras E Garcia J Brunet S Montserrat E CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: High purging efficiency but increased risk of severe infections Exp Hematol 2002 30 824-830 10.1016/S0301-472X(02)00828-7 12135682
13. Barbui AM Galli M Dotti G Belli N Borleri G Gritti G Bellavita P Viero P Comotti B Barbui T Rambaldi A Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma Br J Haematol 2002 116 202-210 10.1046/ j.0007-1048.2001.03189.x 11841418
14. De Vos J Bagnis C Bonnafoux L Requirand G Jourdan M Imbert MC Jourdan E Rossi JF Mannoni P Klein B Comparison of murine leukemia virus, human immunodeficiency virus, and adeno-associated virus vectors for gene transfer in multiple myeloma: Lentiviral vectors demonstrate a striking capacity to transduce low-proliferating primary tumor cells Hum Gene Ther 2003 14 1727-1739 10.1089/104303403322611746 14670124
15. Björkstrand B Dilber MS Smith CIE Gahrton G Xanthopoulos KG Retroviral-mediated gene transfer into myeloma cells Brit J Haematol 1994 88 325-331
16. Bordignon C Bonini C A clinical protocol for gene transfer into peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity in patients affected by recurrent disease after allogeneic bone marrow transplantation Hum Gen Ther 1995 2 813-819
17. Bonini C Ferrari G Verzeletti S Servida P Zappone E Ruggieri L Ponzoni M Rossini S Mavilio F Traversari C Bordignon C HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia Science 1997 276 1719-1724 10.1126/science.276.5319.1719 9180086
18. Deola S Scaramuzza S Birolo RS Carballido-Perrig N Ficara F Mocchetti C Dando J Carballido JM Bordignon C Roncarolo MG Bregni M Aiuti A Mobilized blood CD34+ cells transduced and selected with a clinically applicable protocol reconstitute lymphopoiesis in SCID-Hu mice Hum Gene Ther 2004 15 305-311 10.1089/104303404322886156 15018739
19. Dando JS Aiuti A Deola S Ficara F Bordignon C Optimisation of retroviral supernatant production conditions for the genetic modification of human CD34+ cells J Gene Med 2001 3 219-227 10.1002/1521-2254(200105/ 06)3:3<219::AID-JGM184>3.0.CO;2-E 11437327
20. Stewart AK Prince HM Cappe D Chu P Lutzko C Sutherland DR Dube ID In vitro maintenance and retroviral transduction of human myeloma cells in long-term marrow cultures Cancer Gene Ther 1997 4 148-156 9171933
21. Voena C Ladetto M Astolfi M Provan D Gribben JG Boccadoro M Pileri A Corradini P A novel nested-PCR strategy for the detection of rarranged immunoglobulin heavy-chain genes in B cell tumors Leukemia 1997 1 1793-1798 10.1038/sj.leu.2400801
22. Taswell C Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis J Immunol 1981 126 1614-1619 7009746
23. Deola S Bregni M Ficara F Dando J Bordignon C Aiuti A Efficient ex-vivo immunoselection of ΔNGFR-transduced mobilized CD34+ cells [abstract] Haematologica 1999 84 124
24. Rasmussen T Bjorkstrand B Andersen H Gaarsdal E Johnsen HE Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: A pilot study Exp Hematol 2002 30 82-88 10.1016/ S0301-472X(01)00758-5 11823041
25. Tricot G Gazitt Y Leemhuis T Jagannath S Desikan KR Siegel D Fassas A Tindle S Nelson J Juttner C Tsukamoto A Hallagan J Atkinson K Reading C Hoffman R Barlogie B Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma Blood 1998 91 4489-4495 9616143
26. Kumar A Loughran T Alsina M Durie BGM Djulbegovic B Management of multiple myeloma: A systemic review and critical appraisal of published studies Lancet 2003 4 293-304 10.1016/S1470-2045(03)01077-5
27. Van Riet I Juge-Morineau N Schots R De Waele M De Greef C Thielemans K Van Camp B Bakkus M Persistence of residual tumour cells after cytokine-mediated ex vivo expansion of mobilized CD34+ blood cells in multiple myeloma Br J Haematol 1997 96 403-11 10.1046/ j.1365-2141.1997.d01-2038.x 9029033
28. Widmer L Pichert G Jost LM Stahel RA Fate of contaminating t(14; 18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cells Blood 1996 88 3166-75 8874217
29. Hacein-Bey-Abina S Von Kalle C Schmidt M McCormack MP Wulffraat N Leboulch P Lim A Osborne CS Pawliuk R Morillon E Sorensen R Forster A Fraser P Cohen JI de Saint Basile G Alexander I Wintergerst U Frebourg T Aurias A Stoppa-Lyonnet D Romana S Radford-Weiss I Gross F Valensi F Delabesse E Macintyre E Sigaux F Soulier J Leiva LE Wissler M LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 Science 2003 302 415-9 10.1126/science.1088547 14564000
30. Thrasher AJ Gaspar HB Baum C Modlich U Schambach A Candotti F Otsu M Sorrentino B Scobie L Cameron E Blyth K Neil J Abina SH Cavazzana-Calvo M Fischer A Gene therapy: X-SCID transgene leukaemogenicity Nature 2006 443 7109 1123 10.1038/nature05219
31. Bonini C Grez M Traversari C Ciceri F Marktel S Ferrari G Dinauer M Sadat M Aiuti A Deola S Radrizzani M Hagenbeek A Apperley J Ebeling S Martens A Kolb HJ Weber M Lotti F Grande A Weissinger E Bueren JA Lamana M Falkenburg JH Heemskerk MH Austin T Kornblau S Marini F Benati C Magnani Z Cazzaniga S Safety of retroviral gene marking with a truncated NGF receptor Nat Med 2003 9 367-9 10.1038/nm0403-367 12669036
32. Brenner MK Rill DR Holladay MS Heslop HE Moen RC Buschle M Krance RA Santana VM Anderson WF Ihle JN Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients Lancet 1993 342 1134-7 10.1016/0140-6736(93)92122-A 7901474
33. Brenner MK Rill DR Moen RC Krance RA Mirro J Jr Anderson WF Ihle JN Gene-marking to trace origin of relapse after autologous bone-marrow transplantation Lancet 1993 341 85-6 10.1016/0140-6736(93)92560-G 8093407